Published in J Exp Med on September 06, 2004
Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med (2008) 3.01
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2005) 2.74
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med (2010) 2.26
Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: identification of alpha-ketoglutarate decarboxylase. Proc Natl Acad Sci U S A (2005) 2.07
Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev (2008) 2.01
Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One (2008) 1.91
Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev (2006) 1.82
Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun (2006) 1.63
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun (2005) 1.58
Mycobacterial bacilli are metabolically active during chronic tuberculosis in murine lungs: insights from genome-wide transcriptional profiling. J Bacteriol (2007) 1.40
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis (2008) 1.40
MprAB is a stress-responsive two-component system that directly regulates expression of sigma factors SigB and SigE in Mycobacterium tuberculosis. J Bacteriol (2006) 1.34
Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis (2007) 1.32
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
Cooperative binding of phosphorylated DevR to upstream sites is necessary and sufficient for activation of the Rv3134c-devRS operon in Mycobacterium tuberculosis: implication in the induction of DevR target genes. J Bacteriol (2008) 1.26
Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun (2008) 1.26
Bacterial lifestyle shapes stringent response activation. Trends Microbiol (2013) 1.26
Genome sequence of the Fleming strain of Micrococcus luteus, a simple free-living actinobacterium. J Bacteriol (2009) 1.25
Microarray analysis of whole genome expression of intracellular Mycobacterium tuberculosis. Curr Mol Med (2007) 1.19
Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C. PLoS One (2010) 1.17
The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs. J Infect Dis (2010) 1.13
Adaptation to environmental stimuli within the host: two-component signal transduction systems of Mycobacterium tuberculosis. Microbiol Mol Biol Rev (2011) 1.09
Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol (2009) 1.09
Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo. J Immunol (2012) 1.09
Individual Mycobacterium tuberculosis universal stress protein homologues are dispensable in vitro. Tuberculosis (Edinb) (2010) 1.06
Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev (2014) 1.06
The role of resuscitation promoting factors in pathogenesis and reactivation of Mycobacterium tuberculosis during intra-peritoneal infection in mice. BMC Infect Dis (2007) 1.03
Mycobacterium tuberculosis SigF regulates genes encoding cell wall-associated proteins and directly regulates the transcriptional regulatory gene phoY1. J Bacteriol (2007) 1.03
Within the Enemy's Camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis. Front Immunol (2013) 1.02
RNA profiling in host-pathogen interactions. Curr Opin Microbiol (2007) 1.01
Strains of the East Asian (W/Beijing) lineage of Mycobacterium tuberculosis are DosS/DosT-DosR two-component regulatory system natural mutants. J Bacteriol (2010) 0.99
Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. J Infect Dis (2015) 0.99
Control of cell wall assembly by a histone-like protein in Mycobacteria. J Bacteriol (2007) 0.98
Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis. J Bacteriol (2012) 0.98
Molecular dissection of the mycobacterial stringent response protein Rel. Protein Sci (2006) 0.97
RegAnalyst: a web interface for the analysis of regulatory motifs, networks and pathways. Nucleic Acids Res (2009) 0.97
The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistence. PLoS One (2011) 0.97
Is Mycobacterium tuberculosis stressed out? A critical assessment of the genetic evidence. Microbes Infect (2010) 0.96
Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. Front Microbiol (2014) 0.96
Appropriate DevR (DosR)-mediated signaling determines transcriptional response, hypoxic viability and virulence of Mycobacterium tuberculosis. PLoS One (2012) 0.95
Powerful induction of divergent tgs1-Rv3131 genes in Mycobacterium tuberculosis is mediated by DevR interaction with a high-affinity site and an adjacent cryptic low-affinity site. J Bacteriol (2009) 0.94
PepD participates in the mycobacterial stress response mediated through MprAB and SigE. J Bacteriol (2010) 0.94
Co-expression of DevR and DevR(N)-Aph proteins is associated with hypoxic adaptation defect and virulence attenuation of Mycobacterium tuberculosis. PLoS One (2010) 0.92
In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen. Bioeng Bugs (2011) 0.91
The HtrA-like serine protease PepD interacts with and modulates the Mycobacterium tuberculosis 35-kDa antigen outer envelope protein. PLoS One (2011) 0.89
Components of the Rv0081-Rv0088 locus, which encodes a predicted formate hydrogenlyase complex, are coregulated by Rv0081, MprA, and DosR in Mycobacterium tuberculosis. J Bacteriol (2011) 0.87
Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog (2014) 0.85
Essential roles for Mycobacterium tuberculosis Rel beyond the production of (p)ppGpp. J Bacteriol (2013) 0.85
Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis. MBio (2015) 0.84
Generation of metabolically diverse strains of Streptococcus pyogenes during survival in stationary phase. J Bacteriol (2009) 0.84
A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection. Hum Vaccin Immunother (2013) 0.81
The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence. MBio (2013) 0.81
Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states. Open Biol (2014) 0.81
Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens. Front Microbiol (2015) 0.81
Models of latent tuberculosis: their salient features, limitations, and development. J Lab Physicians (2011) 0.81
MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun (2012) 0.80
Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med (2014) 0.80
A rho GDP dissociation inhibitor produced by apoptotic T-cells inhibits growth of Mycobacterium tuberculosis. PLoS Pathog (2015) 0.80
Experimental Models of Foamy Macrophages and Approaches for Dissecting the Mechanisms of Lipid Accumulation and Consumption during Dormancy and Reactivation of Tuberculosis. Front Cell Infect Microbiol (2016) 0.79
Microarray analysis of the chelerythrine-induced transcriptome of Mycobacterium tuberculosis. Curr Microbiol (2010) 0.79
Novel functions of (p)ppGpp and Cyclic di-GMP in mycobacterial physiology revealed by phenotype microarray analysis of wild-type and isogenic strains of Mycobacterium smegmatis. Appl Environ Microbiol (2015) 0.79
senX3-independent contribution of regX3 to Mycobacterium tuberculosis virulence. BMC Microbiol (2014) 0.79
The MprB extracytoplasmic domain negatively regulates activation of the Mycobacterium tuberculosis MprAB two-component system. J Bacteriol (2013) 0.78
Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection. Infect Immun (2014) 0.78
M. tuberculosis Gene Expression during Transition to the "Non-Culturable" State. Acta Naturae (2009) 0.78
Understanding communication signals during mycobacterial latency through predicted genome-wide protein interactions and boolean modeling. PLoS One (2012) 0.78
Investigation of functional activity of cells in granulomatous inflammatory lesions from mice with latent tuberculous infection in the new ex vivo model. Clin Dev Immunol (2013) 0.78
Rv1894c is a novel hypoxia-induced nitronate monooxygenase required for Mycobacterium tuberculosis virulence. J Infect Dis (2013) 0.78
Mycobacterium tuberculosis Transcription Machinery: Ready To Respond to Host Attacks. J Bacteriol (2016) 0.77
Dormant non-culturable Mycobacterium tuberculosis retains stable low-abundant mRNA. BMC Genomics (2015) 0.77
Differential regulation of the two-component regulatory system senX3-regX3 in Mycobacterium tuberculosis. Microbiology (2014) 0.77
Regulation of Growth, Cell Shape, Cell Division, and Gene Expression by Second Messengers (p)ppGpp and Cyclic Di-GMP in Mycobacterium smegmatis. J Bacteriol (2016) 0.77
Mycobacterial Dormancy Systems and Host Responses in Tuberculosis. Front Immunol (2017) 0.77
In silico identification of common epitopes from pathogenic mycobacteria. BMC Immunol (2013) 0.76
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. J Med Chem (2016) 0.76
A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis. Gut Pathog (2009) 0.76
Targeting multiple response regulators of Mycobacterium tuberculosis augments the host immune response to infection. Sci Rep (2016) 0.76
Evolution of Mycolic Acid Biosynthesis Genes and Their Regulation during Starvation in Mycobacterium tuberculosis. J Bacteriol (2015) 0.76
Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci Rep (2017) 0.75
The unique regulation of the DosR regulon in the Beijing lineage of Mycobacterium tuberculosis. J Bacteriol (2016) 0.75
Mycobacterium tuberculosis P-type ATPases: possible targets for drug or vaccine development. Biomed Res Int (2014) 0.75
Mycobacterial DNA-binding protein 1 is critical for long term survival of Mycobacterium smegmatis and simultaneously coordinates cellular functions. Sci Rep (2017) 0.75
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 11.48
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med (2003) 10.67
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol (2002) 8.90
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A (2001) 7.65
The sigma factors of Bacillus subtilis. Microbiol Rev (1995) 5.76
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol (2003) 5.68
Clinical practice. Latent tuberculosis infection. N Engl J Med (2002) 5.64
In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria. Proc Natl Acad Sci U S A (1999) 4.97
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol (1996) 4.05
Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet (2001) 3.71
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis (1989) 3.69
The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A (2004) 3.63
Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A (2002) 3.50
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol (2002) 3.35
Tuberculosis: latency and reactivation. Infect Immun (2001) 3.15
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
In vivo cultivation of tumor cells in hollow fibers. Life Sci (1995) 2.29
The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems. J Antimicrob Chemother (1992) 1.87
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother (2003) 1.81
pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology (2003) 1.61
A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis (1992) 1.50
Sigma factors of Mycobacterium tuberculosis. Tuber Lung Dis (1997) 1.40
The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. Infect Dis Clin North Am (2002) 1.39
In vivo veritas: the search for TB drug targets goes live. Nat Med (2000) 1.36
Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev (1981) 1.30
Production of avirulent mutants of Mycobacterium bovis with vaccine properties by the use of illegitimate recombination and screening of stationary-phase cultures. Microbiology (2002) 1.24
Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology (1990) 1.03
Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther (1993) 1.00
Interruption of the phosphoglucose isomerase gene results in glucose auxotrophy in Mycobacterium smegmatis. J Bacteriol (1997) 0.97
In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model. Bioorg Med Chem Lett (1999) 0.83
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother (2007) 3.41
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (2009) 3.39
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Extensively drug-resistant tuberculosis. Lancet Infect Dis (2008) 3.21
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 2.13
Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2002) 2.05
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother (2002) 2.03
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol (2004) 1.96
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med (2010) 1.91
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Copper resistance is essential for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2011) 1.76
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother (2009) 1.72
Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis (2010) 1.69
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun (2003) 1.63
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun (2005) 1.58
A novel copper-responsive regulon in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.56
Short report: modulation of Mycobacterium tuberculosis infection by Plasmodium in the murine model. Am J Trop Med Hyg (2004) 1.54
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Polymerized human Hb use in acute chest syndrome: a case report. Transfusion (2002) 1.51
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol (2004) 1.48
Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother (2006) 1.48
Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol (2009) 1.47
Evidence that the Streptomyces developmental protein WhiD, a member of the WhiB family, binds a [4Fe-4S] cluster. J Biol Chem (2004) 1.42
Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.42
Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect Immun (2004) 1.41
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis (2008) 1.40
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother (2010) 1.40
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
"Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates. Mol Cell (2010) 1.37
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2008) 1.37
Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis (2010) 1.36
Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med (2009) 1.36
Phosphate depletion: a novel trigger for Mycobacterium tuberculosis persistence. J Infect Dis (2009) 1.35
Deletion of Mycobacterium tuberculosis sigma factor E results in delayed time to death with bacterial persistence in the lungs of aerosol-infected mice. Infect Immun (2003) 1.34
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med (2005) 1.31
Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother (2007) 1.29
Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun (2008) 1.26
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2011) 1.24
Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother (2011) 1.24
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
Characterization of the Mycobacterium tuberculosis sigma factor SigM by assessment of virulence and identification of SigM-dependent genes. Infect Immun (2006) 1.23
Pathogenesis of central nervous system tuberculosis. Curr Mol Med (2009) 1.22
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A (2012) 1.22
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.21
Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med (2013) 1.20
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol (2011) 1.20
Isolation of acid-inducible genes of Mycobacterium tuberculosis with the use of recombinase-based in vivo expression technology. Infect Immun (2003) 1.20
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med (2008) 1.19
A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res (2013) 1.17
The Mycobacterium tuberculosis SigD sigma factor controls the expression of ribosome-associated gene products in stationary phase and is required for full virulence. Cell Microbiol (2005) 1.16